I'm Calling It: Medtronic (MDT) Will Soar 40% by the End of 2026

Medtronic's stock has declined over 30% in the past five years due to cost pressures and competitive challenges, but analyst Leo Sun believes it could rise 40% to $121 by end of 2026. The company's recent diabetes unit spinoff, business restructuring focused on higher-margin cardiovascular and neuroscience portfolios, and strong revenue growth (8.4% in fiscal 2026) position it for recovery. Trading at 18x forward earnings with a 3.3% dividend yield and potential Dividend King status next year, Medtronic could attract significant investor attention.